anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acyclovir Sodium Injection is a synthetic nucleoside analog, active against herpes viruses. It is a sterile, aqueous solution for intravenous infusion, containing 50 mg acyclovir per mL in Water for Injection, USP. The concentration is equivalent to 54.9 mg of acyclovir sodium per mL in Water for Injection, USP. The sodium content is approximately 5.1 mg/mL. The pH range of the solution is 10.85 to 11.50. Further dilution of Acyclovir Sodium Injection in an appropriate intravenous solution must be performed before infusion (see DOSAGE AND ADMINISTRATION, Administration).  
  
The chemical name of acyclovir sodium is 9-[(2-Hydroxyethoxy)methyl] guanine, and has the following structural formula:

  


  


Acyclovir USP is a white to off-white, crystalline powder. Acyclovir sodium is the sodium salt of acyclovir, which is formed in situ, with the molecular formula C8H10N5NaO3 and a molecular weight of 247.19. The maximum solubility in water at 25°C exceeds 100 mg/mL. At physiologic pH, acyclovir sodium exists as the unionized form with a molecular weight of 225 and a maximum solubility in water at 37°C of 2.5 mg/mL. The pka’s of acyclovir are 2.27 and 9.25.
It has been estimated that in 2010, over two million patients with end-stage kidney disease may have faced premature death due to a lack of access to affordable renal replacement therapy, mostly dialysis. To address this shortfall in dialytic kidney replacement therapy, we propose a novel, cost-effective, and low-complexity hemodialysis method called allo-hemodialysis (alloHD). With alloHD, instead of conventional hemodialysis, the blood of a patient with kidney failure flows through the dialyzer's dialysate compartment counter-currently to the blood of a healthy subject (referred to as a "buddy") flowing through the blood compartment. Along the concentration and hydrostatic pressure gradients, uremic solutes and excess fluid are transferred from the patient to the buddy and subsequently excreted by the healthy kidneys of the buddy. We developed a mathematical model of alloHD to systematically explore dialysis adequacy in terms of weekly standard urea Kt/V. We showed that in the case of an anuric child (20 kg), four 4 h alloHD sessions are sufficient to attain a weekly standard Kt/V of >2.0. In the case of an anuric adult patient (70 kg), six 4 h alloHD sessions are necessary. As a next step, we designed and built an alloHD machine prototype that comprises off-the-shelf components. We then used this prototype to perform ex vivo experiments to investigate the transport of solutes, including urea, creatinine, and protein-bound uremic retention products, and to quantitate the accuracy and precision of the machine's ultrafiltration control. These experiments showed that alloHD performed as expected, encouraging future in vivo studies in animals with and without kidney failure.
Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
The invention relates to Banxia Houpo Tang integrated novel dosage form preparation technology and a production method thereof. TheBanxia Houpo Tang integrated novel dosage form contains the following raw materials by weight portions: 12 portions of Banxia, 9 portions of Houpo, 12 portions of tackahoe, 9 portions of gingers and 6 portions of folium. The production process includes the following steps of pulverization by ultrasonic airflow, extraction by alcohol water, pulverization and extraction by ultrasonic wave, concentration by decocting, drying by ultrasonic sprayer, nanometer grinding, high-pressure homogenization, nano-grain preparation and the like. The preparation technology has the advantages of nanometer carrier coupling technique such as multiple cooperations, multiple targets and the like. After the mass production is realized, the production cost can be greatly reduced, the product quality can be greatly improved, and the targeting and the slow release property of the medicine are stronger. The medicine can be taken orally or used externally and can be taken in four periods of time according to the midnight-noon ebb-flow and the blood circulation principle of the human body. The medicine also can be prepared into a membrane form and a transdermal agent to be respectively adhered onto different parts of the human body according to the midnight-noon ebb-flow and the blood circulation principle of the human body and can be directly absorbed by the skin.
A novel method of chemical ligation of peptide segments requires no protecting groups and no activation of the C-α carboxyl groups. The method consists of four steps: (1) aldehyde initiation in which a masked glycolaldehyde ester is linked to the carboxylic group of an unprotected peptide by enzymatic reaction; (2) ring formation - the regenerated aldehyde reacts with the N-α amine of the second unprotected peptide; (3) rearrangement where O-acyl linkage is transferred to N-acyl linkage to form a peptide bond at higher pH; (4) reconversion to the natural amino acids if necessary. This invention also relates to a method for ligating unprotected peptide, proteins or nonpeptide segments to give therapeutic products and synthetic vaccines with linear, circularized, or branched backbone structures. The method embraces the discovery that when a weakly basic nucleophile and aldehyde are used as a reacting pair for the ligation of two segments, the initial covalent formation of thiazolidine, oxazolidine, hydrozone and oxime bonds is highly specific and may undergo a subsequent intramolecular O to N-acyl rearrangement step which results in the formation of amide bond. Weak bases on a peptide segment are those that contain 1,2- or 1,3-amino thiol or alcohol or those that contain an electronic withdrawing group to the amine such as hydrazide, oxime, phenylhydrazine. Unprotected peptides containing amino terminal residues of cysteine, serine, or threonine can therefore be served as a weak base or as a masked aldehyde which can be generated by oxidation. This invention also relates to a method using the same concept of weak base-aldehyde ligation for site-specific modification of peptides or proteins by lipidation and pegylation. More particularly, the invention relates to the modification of the protein gp120 derived from the human immunodeficiency virus-1 at the amino terminus to contain one or more lipid side chains (lipidation) to increase its efficacy for vaccine and the modificacition of cytokine interleukin-2 by polyethylene glycol (PEG, pegylation) to increase its stability.
The present application provides an AI-based system for evaluating an individual's mindfulness (e.g., during prayer) based on video captured of the individual. In one example, the video may be captured via a smart phone. The individual's mindfulness may be continually evaluated from the captured video by observing the individual's body pose and movements. For instance, turning the individual's head to one side or moving the individual's eyes around rapidly can be signs of losing focus. Body pose and movement information of an individual may be derived from the video through AI-based video analytics. The user's body pose and movements may be checked against a set of predefined criteria for mindfulness, and an objective evaluation may be provided. Such evaluation can then be fed back to the individual, for example, to remind the individual whenever they lose focus during prayer.
Patients receive cabozantinib PO QD on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography during screening and undergo CT or MRI, bone scan and blood and urine sample collection throughout the trial and may undergo PET/CT throughout the trial.
PURPOSE: Bariatric surgery remains the most efficient treatment to achieve a sustained weight loss. However, a large proportion of patients experience suboptimal weight loss (SWL). The exact mechanisms involved remain to be fully elucidated, but the homeostatic appetite control system seems to be involved. The aim of this study was, therefore, to compare the plasma concentration of gastrointestinal hormones, and appetite ratings, between those experiencing SWL and optimal weight loss (OWL) after Roux-en-Y gastric bypass (RYGB).
MATERIALS AND METHODS: Fifty participants from the Bariatric Surgery Observation Study (BAROBS) experiencing either SWL or OWL (< or ≥ 50% of excess weight loss (EWL), respectively) > 13 years post-RYGB were compared to 25 non-surgical controls. Plasma concentrations of acylated ghrelin (AG), total glucagon-like peptide-1 (GLP-1), total peptide YY (PYY), cholecystokinin (CCK), and subjective ratings of hunger, fullness, desire to eat (DTE), and prospective food consumption (PFC) were assessed in the fasting and postprandial (area under the curve (AUC)) states.
RESULTS: Those experiencing OWL presented with higher basal AG and GLP-1 iAUC, and lower AG iAUC compared with SWL and controls. Additionally, both bariatric groups presented with higher PYY and CCK iAUC compared to controls. PFC tAUC was also lower in OWL compared to the SWL group. Total weight loss was positively correlated with GLP-1 tAUC and negatively correlated with fasting and tAUC DTE and PFC tAUC.
CONCLUSIONS: SWL > 13 years post-RYGB is associated with lower basal ghrelin, as well as a weaker satiety response to a meal. Future studies should investigate the causality of these associations.
Tumor hypoxia-associated drug resistance presents a major challenge for cancer chemotherapy. However, sustained delivery systems with a high loading capability of hypoxia-inducible factor-1 (HIF-1) inhibitors are still limited. Here, we developed an ultrastable iodinated oil-based Pickering emulsion (PE) to achieve locally sustained codelivery of a HIF-1 inhibitor of acriflavine and an anticancer drug of doxorubicin for tumor synergistic chemotherapy. The PE exhibited facile injectability for intratumoral administration, great radiopacity for in vivo examination, excellent physical stability (>1 mo), and long-term sustained release capability of both hydrophilic drugs (i.e., acriflavine and doxorubicin). We found that the codelivery of acriflavine and doxorubicin from the PE promoted the local accumulation and retention of both drugs using an acellular liver organ model and demonstrated significant inhibition of tumor growth in a 4T1 tumor-bearing mouse model, improving the chemotherapeutic efficacy through the synergistic effects of direct cytotoxicity with the functional suppression of HIF-1 pathways of tumor cells. Such an iodinated oil-based PE provides a great injectable sustained delivery platform of hydrophilic drugs for locoregional chemotherapy.
In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
<P>PROBLEM TO BE SOLVED: To provide a tablet having high adhesion between an outer shell and an inside area and scarcely causing crack or peeling.  <P>SOLUTION: This tablet 1 is formed by integrally molding the inside area 3 formed by applying compression molding to powder components, with the outer shell 2 containing components different from the powder. The outer shell 2 is formed of component melting by ultrasonic vibration. Preferably, the outer shell 2 and the inside area 3 are integrally molded while applying the ultrasonic vibration. This tablet 1 is manufactured by filling a tablet molding die with mixture including raw material powder, and compressing the mixture while applying ultrasonic vibration thereto via molding pestle. In prior to filling the die with the mixture, a melting component is attached to the inside of the die and the surface of the molding pestle by the ultrasonic vibration.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
The present invention relates to a method of using a magnetic force of a magnet, and more specifically, to a method of treating a prostate disease with a magnet by using a principle in which hemoglobin in blood is a ferromagnetic substance. When prostate gland in men is enlarged, there may be six specific symptoms of prostate diseases such as pain or an unpleasant feeling felt in the perineum between testicles and anus, pain or an unpleasant feeling felt in the testicles, pain and an unpleasant feeling at the end of the penis felt regardless of urination, pain or an unpleasant feeling felt in the pubis below the waist or the bladder (lower abdomen), painful urination, and pain or an unpleasant feeling felt during or after ejaculation. The prostate gland is located between the pubic bone and rectum, just below the bladder, within the pelvis, and can be touched through the anus. The causes of prostate disease are known to be bacterial infections, immune disorders, a venous circulatory disorder in the prostate gland, and urinary reflux caused by problems in the prostate sphincter. Treatment of prostate diseases includes general therapies and therapies using devices, all of which are focused on promotion of blood flow in the prostate tissue and loss of necrotic inflammatory cells. According to the present invention, an enlarged prostate tissue can be rapidly restored to a normal tissue by vigorous blood circulation, and accordingly, symptoms of the prostate diseases can be alleviated for a relatively short period of time at low costs by a relatively simple method, and thus, the present invention may be used effectively in treating prostate diseases.
This was a retrospective comparative study spanning January 2014 to December 2018. It was conducted at Jordan university hospital, a teaching referral hospital affiliated to the University of Jordan, Amman, Jordan. Pregnant patients, both primigravida and multipara who had a spontaneous singleton pregnancy with documented TSH level in the first 16 weeks' gestation were included. The investigators excluded all patients who had known thyroid dysfunction whether on treatment or not, molar pregnancies, multiple pregnancies, patients with hyperemesis gravidarum, all patients with anti-thyroid antibodies (Anti-TPO), patients with TSH ˃ 4.0 mIU/L or ˂ 0.1 mIU/L. This range was used as TSH ˂ 0.1 mIU/L indicated an undiagnosed subclinical hyperthyroidism and TSH ˃4.0 indicated undiagnosed hypothyroidism. In addition, there were wide variations in the TSH reference ranges. Participants' data were collected retrospectively from antenatal clinic notes, admission notes, labor ward and operative notes. Data included patients ID number, age, parity, body mass index (BMI) in kg/m2, TSH values in the first 16 weeks of pregnancy. The participants were divided into 2 groups according to their TSH values. Group one with TSH values between 0.1-1.99 mIU/L. Group 2 had TSH values between 2-4 mIU/L. Each group was then subdivided into 2 subgroups; primigravida and multipara. Group P1: Primigravida in group 1, Group P2: Primigravida in group 2, Group M1: Multiparous in group 1, Group M2: Multiparous in group 2.

The investigators calculated the mean, median and range of TSH in each subgroup. The feto-maternal outcome was then compared between the 2 groups. The investigators studied miscarriage rate, ectopic pregnancy rate, maternal blood sugar values (Fasting blood sugar (FBS), glucose tolerance test (GTT), HbA1c or a combination) between 26 and 34 weeks, development of high blood pressure at delivery, duration of pregnancy (gestational age at delivery), preterm delivery rate, abruption placenta, mode of delivery, birth weight and APGAR score at 1 and 5 minutes. Gestational diabetes mellitus (GDM) was diagnosed as an FBS 92-125 mg/dL or 1-hour plasma glucose levels of 180 or more following 75-gram oral glucose load or 2-hour plasma glucose 153-199 mg/dL. The study obtained the approval of the institutional review board (IRB) at Jordan University Hospital (JUH) number 179/2019 dated 17/4/2019.

The statistical analysis was performed with the Data Toolkit in Excel (Microsoft, Redmond, WA, USA) using descriptive analysis. Relative risk and 95% confidence intervals were also calculated to compare variables. P values were considered significant at ˂0.05. The obtained data were examined using a frequency table and are presented as frequency, percentage and mean
Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
Patients undergoing septoplasty operation will be included to this study. After coming to operation room all the patients will have standard monitorisation and induction. After intubation they will have inhalational anesthesia as maintenance. According to the TOF (train of four) measurement all patient will have neuromuscular relaxant if needed. After the operation they will be extubated according to TOF or clinical parameters. And time for extubation, mask assistance need, any complication, mask difficulty, and time spent in postoperative care unit will be recorded. Then the results will be compared, whether sugammadex or neostigmine is better for these patients in means of extubation and postoperative status.
The invention discloses a taxus chinensis seed anti-tumor active part and liposome prepared by the same, wherein the extraction process adopted by the taxus chinensis seed anti-tumor active part is that the extraction solvent is 40% -80% ethanol; the mass ratio of the feed liquid is 1:40-60, the extraction time is 30-50 min, and the extraction temperature is 40-70 ℃. Macroporous adsorption resin and silica gel are adopted for separation and purification. The extraction method of the active site of the taxus chinensis seed is simple, easy to operate, and the separation and purification method has good separation effect, and can reduce the production cost after the recovery of ethanol, methanol and petroleum ether is controlled, and basically has no environmental pollution. The preparation method of the liposome is simple, easy to operate and low in cost, and meanwhile, the use of toxic solvents is avoided; the particle size of the prepared liposome is about 115 nm. The cumulative dissolution rate of the liposome in different dissolution media is more than 80% in 15min, and the cumulative release rate of the liposome in 1h min reaches the plateau phase, so that the drug is basically completely released. Remarkably improves the dissolubility and in vitro release degree of the anti-tumor active part of the taxus chinensis seeds.
<P>PROBLEM TO BE SOLVED: To provide formulations for protecting, preventing, improving or treating diseases or conditions relevant to abnormalities or low levels of n-3 or n-6 PUFA (polyunsaturated fatty acid) in blood.  <P>SOLUTION: Edible formulations comprise arachidonic acid (ARA). They are adapted to deliver from 150 mg to 1 g per day of ARA and may contain other PUFAs, for example docosahexaenoic acid (DHA). The DHA dosage is from 400 to 600 mg per day, and the ratio of ARA:DHA may be from 1:5 to 5:1. The formulations are pharmaceutical compositions comprising ARA and DHA at a ratio of ARA:DHA of 1:1 to 1:2, and are foodstuffs comprising 0.1 to 5% ARA. Such formulations can be used to increase ARA levels in vivo, for example in pregnant women or for people who have diseases or conditions associated with low ARA levels.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
Hypothesis: rEV131, a histamine binding protein (derived from tick saliva) with an affinity for histamine 10 - 100 fold that of natural histamine receptors, might attenuate Nasal Allergen Challenge (NAC) induced allergic rhinitis.

Methods: Patients with known ragweed allergy will be screened to determine the minimal threshold concentration (PD30) of pollen extract that consistently induces the four key symptoms of allergic rhinitis: itch, sneezing, congestion and mucus production. A standardised system of TNSS scoring will be used. A total of 112 eligible patients will be randomised in double blind fashion to receive one of four concentrations of rEV131 (0.63, 1.25, 2.5 and 5.0 mg/ml) by nasal spray 30 minutes prior to NAC or placebo. Symptoms will be scored at 15, 30 and 45 minutes post NAC. Mean sum of symptom scores of all active medication treated patients will be compared with those of placebo treated patients. The primary analysis will be the sum of scores at 15 minutes post challenge for the optimum concentration of rEV131. Secondary outcome variables will include comparison of individual symptom and percentage of patients having a clinically significant response.